Wang Xu - NovaBay Pharmaceuticals Controller and Senior Manager
| NBY Stock | USD 0.57 0.03 5.00% |
Insider
Wang Xu is Controller and Senior Manager of NovaBay Pharmaceuticals since 2019.
| Age | 36 |
| Tenure | 5 years |
| Address | 2000 Powell Street, Emeryville, CA, United States, 94608 |
| Phone | 510 899 8800 |
| Web | https://novabay.com |
NovaBay Pharmaceuticals Management Efficiency
The company has Return on Asset of (0.3867) % which means that on every $100 spent on assets, it lost $0.3867. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (2.6383) %, meaning that it generated no profit with money invested by stockholders. NovaBay Pharmaceuticals' management efficiency ratios could be used to measure how well NovaBay Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.12 in 2024. Return On Capital Employed is likely to drop to -1.1 in 2024. At this time, NovaBay Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 2 M in 2024, whereas Other Assets are likely to drop slightly above 461.6 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Robert McRae | Palisade Bio | N/A | |
| DSc MSE | Immix Biopharma | 75 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| MBA IV | Enveric Biosciences | 68 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Sharon McBrayer | Palisade Bio | N/A | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Jean Lechance | Altamira Therapeutics | N/A | |
| Nandan BS | Immix Biopharma | 62 | |
| MD FAAAAI | Palisade Bio | N/A | |
| Marcel CPA | Altamira Therapeutics | 66 | |
| MBA MD | Immix Biopharma | 49 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| JD MBA | Immix Biopharma | N/A | |
| Samuel MD | Altamira Therapeutics | 71 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Gabriel BA | Immix Biopharma | 37 | |
Management Performance
| Return On Equity | -2.64 | ||||
| Return On Asset | -0.39 |
NovaBay Pharmaceuticals Leadership Team
Elected by the shareholders, the NovaBay Pharmaceuticals' board of directors comprises two types of representatives: NovaBay Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NovaBay. The board's role is to monitor NovaBay Pharmaceuticals' management team and ensure that shareholders' interests are well served. NovaBay Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NovaBay Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiaopei Wang, Director | ||
| Andrew Jones, Chief Financial Officer, Treasurer | ||
| Swan Sit, Independent Director | ||
| Mijia Wu, Director | ||
| Audrey MD, Chief Director | ||
| Paul Freiman, Independent Chairman of the Board | ||
| Jeffrey MD, Pres DERMAdoctor | ||
| Justin Esq, CEO and President | ||
| Yenyou Zheng, Independent Director | ||
| Justin Hall, President, Chief Executive Officer, Director | ||
| Tommy Law, Interim Controller | ||
| Wang Xu, Controller and Senior Manager | ||
| Xinzhou Li, Director |
NovaBay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NovaBay Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.64 | ||||
| Return On Asset | -0.39 | ||||
| Profit Margin | (0.77) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 3.43 M | ||||
| Shares Outstanding | 4.89 M | ||||
| Shares Owned By Insiders | 0.02 % | ||||
| Shares Owned By Institutions | 2.58 % | ||||
| Number Of Shares Shorted | 187.04 K | ||||
| Price To Earning | (5.43) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.